Important Mantle Cell Lymphoma Findings From the Sympatico Study

How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center in Houston, told the conference how a combination of two targeted drugs—ibrutinib and venetoclax—improved outcomes.